These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 24321258)

  • 1. Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature.
    Bjarnason GA; Khalil B; Hudson JM; Williams R; Milot LM; Atri M; Kiss A; Burns PN
    Urol Oncol; 2014 May; 32(4):480-7. PubMed ID: 24321258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reprint of: Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: Correlation with dynamic microbubble ultrasound data and review of the literature.
    Bjarnason GA; Khalil B; Hudson JM; Williams R; Milot LM; Atri M; Kiss A; Burns PN
    Urol Oncol; 2015 Apr; 33(4):171-8. PubMed ID: 25934535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma.
    Rautiola J; Utriainen T; Peltola K; Joensuu H; Bono P
    Acta Oncol; 2014 Jan; 53(1):113-8. PubMed ID: 23721300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.
    Bracarda S; Iacovelli R; Boni L; Rizzo M; Derosa L; Rossi M; Galli L; Procopio G; Sisani M; Longo F; Santoni M; Morelli F; Di Lorenzo G; Altavilla A; Porta C; Camerini A; Escudier B;
    Ann Oncol; 2015 Oct; 26(10):2107-13. PubMed ID: 26216384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilization of Sunitinib for Renal Cell Cancer: an Egyptian University hospital experience.
    M Eel D
    Asian Pac J Cancer Prev; 2016; 17(7):3161-6. PubMed ID: 27509945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the MSKCC and Heng risk criteria models for predicting survival in patients with metastatic renal cell carcinoma treated with sunitinib.
    Kwon WA; Cho IC; Yu A; Nam BH; Joung JY; Seo HK; Lee KH; Chung J
    Ann Surg Oncol; 2013 Dec; 20(13):4397-404. PubMed ID: 24081805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
    Powles T; Blank C; Chowdhury S; Horenblas S; Peters J; Shamash J; Sarwar N; Boleti E; Sahdev A; O'Brien T; Berney D; Beltran L; Nathan P; Haanen J; Bex A
    Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.
    Keizman D; Sarid D; Lee JL; Sella A; Gottfried M; Hammers H; Eisenberger MA; Carducci MA; Sinibaldi V; Neiman V; Rosenbaum E; Peer A; Neumann A; Mermershtain W; Rouvinov K; Berger R; Yildiz I
    Oncologist; 2016 Oct; 21(10):1212-1217. PubMed ID: 27382030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma.
    Iacovelli R; Massari F; Albiges L; Loriot Y; Massard C; Fizazi K; Escudier B
    Eur Urol; 2015 Jul; 68(1):154-60. PubMed ID: 25466943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha.
    Dirican A; Kucukzeybek Y; Erten C; Somali I; Demir L; Can A; Payzin KB; Bayoglu IV; Akyol M; Yildiz Y; Koeseoglu M; Alacacioglu A; Tarhan MO
    Asian Pac J Cancer Prev; 2013; 14(3):2101-5. PubMed ID: 23679326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Standard vs adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: results from a large retrospective analysis.
    De Giorgi U; Scarpi E; Sacco C; Aieta M; Lo Re G; Sava T; Masini C; De Vincenzo F; Baldazzi V; Camerini A; Fornarini G; Burattini L; Rosti G; Ferrari V; Moscetti L; Chiuri VE; Luzi Fedeli S; Amadori D; Basso U
    Clin Genitourin Cancer; 2014 Jun; 12(3):182-9. PubMed ID: 24369790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of sunitinib for advanced non-clear cell renal cell carcinoma.
    Shi HZ; Tian J; Li CL
    Asia Pac J Clin Oncol; 2015 Dec; 11(4):328-33. PubMed ID: 26471774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sunitinib dose-escalation after disease progression in metastatic renal cell carcinoma.
    Raphael J; Thawer A; Bjarnason GA
    Urol Oncol; 2018 Jan; 36(1):12.e1-12.e6. PubMed ID: 28966072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
    Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
    Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α.
    Tsimafeyeu I; Zart JS; Chung B
    BJU Int; 2013 Jul; 112(1):32-8. PubMed ID: 23746142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†.
    Ravaud A; Oudard S; De Fromont M; Chevreau C; Gravis G; Zanetta S; Theodore C; Jimenez M; Sevin E; Laguerre B; Rolland F; Ouali M; Culine S; Escudier B
    Ann Oncol; 2015 Jun; 26(6):1123-1128. PubMed ID: 25802238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.
    Choueiri TK; Plantade A; Elson P; Negrier S; Ravaud A; Oudard S; Zhou M; Rini BI; Bukowski RM; Escudier B
    J Clin Oncol; 2008 Jan; 26(1):127-31. PubMed ID: 18165647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
    Xie M; He CS; Huang JK; Lin QZ
    Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma.
    Elfiky AA; Cho DC; McDermott DF; Rosenberg JE; Fortner B; Antràs L; Chen K; Sheng Duh M; Jayawant SS; Oh WK; Atkins MB; Choueiri TK
    Urol Oncol; 2011; 29(6):756-63. PubMed ID: 20451414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VEGF expression and response to sunitinib in patients with metastatic clear cell renal cell carcinoma.
    Minardi D; Lucarini G; Santoni M; Mazzucchelli R; Burattini L; Pistelli M; Bianconi M; Di Primio R; Scartozzi M; Montironi R; Cascinu S; Muzzonigro G
    Anticancer Res; 2013 Nov; 33(11):5017-22. PubMed ID: 24222145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.